LCZ696 (a combination therapy of an angiotensin receptor blocker and a neprilysin inhibitor) demonstrated superiority over angiotensin converting enzyme (ACE) inhibitors in 8399 patients with HF and reduced ejection function (HFrEF), with a reduction in the risk of all‐cause mortality of 12.6% (95% CI 7–18%; P < 0.0001) (Packer et al., 2015). This evidence concerns the gene ACE and hydrops fetalis.